Aethlon Medical (NASDAQ:AEMD) Stock Rating Upgraded by ValuEngine

Aethlon Medical (NASDAQ:AEMD) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Friday, ValuEngine reports.

Shares of AEMD stock opened at $0.33 on Friday. Aethlon Medical has a 52-week low of $0.30 and a 52-week high of $1.74. The firm has a market cap of $6.26 million, a PE ratio of -0.97 and a beta of 1.29. The firm has a fifty day simple moving average of $0.36.

A hedge fund recently bought a new stake in Aethlon Medical stock. Bank of New York Mellon Corp bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,363 shares of the medical equipment provider’s stock, valued at approximately $50,000. Bank of New York Mellon Corp owned about 0.17% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.33% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals.

Featured Story: Initial Public Offering (IPO)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.